<3-<(benzyloxycarbonyl)amino>-2-oxo-6-phenethyl-1,2-dihydro-1-pyridyl>acetic acid | 147269-13-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: <3-<(benzyloxycarbonyl)amino>-2-oxo-6-phenethyl-1,2-dihydro-1-pyridyl>acetic acid
• 英文别名: (3-benzyloxycarbonylamino-2-oxo-6-phenethyl-1,2-dihydro-1-pyridyl)acetic acid；2-[2-oxo-6-(2-phenylethyl)-3-(phenylmethoxycarbonylamino)pyridin-1-yl]acetic acid
• CAS: 147269-13-4
• 化学式: C₂₃H₂₂N₂O₅
• 分子量: 406.438
• InChiKey: AXAQBFCUJHRELB-UHFFFAOYSA-N

物化性质

• 沸点：
  654.8±55.0 °C(predicted)
• 密度：
  1.33±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  30
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  95.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  <3-<(benzyloxycarbonyl)amino>-2-oxo-6-phenethyl-1,2-dihydro-1-pyridyl>acetic acid 在 N-甲基吗啉 、 二氯乙酸 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 1-羟基苯并三唑一水物 作用下， 以 四氢呋喃 、 二甲基亚砜 、 甲苯 为溶剂， 反应 48.0h， 生成 {2-Oxo-6-phenethyl-1-[(3,3,3-trifluoro-1-isopropyl-2-oxo-propylcarbamoyl)-methyl]-1,2-dihydro-pyridin-3-yl}-carbamic acid benzyl ester
  参考文献：
  名称：

  Nonpeptidic Inhibitors of Human Leukocyte Elastase. 2. Design, Synthesis, and in vitro Activity of a Series of 3-Amino-6-aryl-2-oxopyridyl Trifluoromethyl Ketones

  摘要：

  A series of potent nonpeptidic inhibitors of the enzyme human leukocyte elastase (HLE) is reported. These inhibitors contain a 3-amino-2-pyridone ring as a central template in which the pyridone carbonyl and 3-position NH group are thought to form important hydrogen bonding interactions with the Val-216 residue of HLE. Substitution of the 6-position of the pyridone ring by various alkyl and aryl groups was found to afford increases in the in vitro potency of these inhibitors. A 6-position phenyl group, compound 10f, was found to result in a large increase in binding affinity, which was not obtained when the phenyl group was placed in either the 4- or 5-position of the molecule. Compound 10f was found to have good selectivity for HLE over other proteolytic enzymes, with the exception of bovine pancreatic chymotrypsin (BPC). Substitution of the 6-phenyl group in these molecules was found to decrease binding affinity for BPC without adversely affecting affinity for HLE.

  DOI：

  10.1021/jm00046a015
• 作为产物：
  描述：

  3-氰基-6-甲基-2(1H)-吡啶酮 在 二苯基磷酸 、 氢溴酸 、 sodium hydride 、 三乙胺 、 三氟乙酸 、 lithium diisopropyl amide 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 溶剂黄146 为溶剂， 反应 40.5h， 生成 <3-<(benzyloxycarbonyl)amino>-2-oxo-6-phenethyl-1,2-dihydro-1-pyridyl>acetic acid
  参考文献：
  名称：

  Nonpeptidic Inhibitors of Human Leukocyte Elastase. 2. Design, Synthesis, and in vitro Activity of a Series of 3-Amino-6-aryl-2-oxopyridyl Trifluoromethyl Ketones

  摘要：

  A series of potent nonpeptidic inhibitors of the enzyme human leukocyte elastase (HLE) is reported. These inhibitors contain a 3-amino-2-pyridone ring as a central template in which the pyridone carbonyl and 3-position NH group are thought to form important hydrogen bonding interactions with the Val-216 residue of HLE. Substitution of the 6-position of the pyridone ring by various alkyl and aryl groups was found to afford increases in the in vitro potency of these inhibitors. A 6-position phenyl group, compound 10f, was found to result in a large increase in binding affinity, which was not obtained when the phenyl group was placed in either the 4- or 5-position of the molecule. Compound 10f was found to have good selectivity for HLE over other proteolytic enzymes, with the exception of bovine pancreatic chymotrypsin (BPC). Substitution of the 6-phenyl group in these molecules was found to decrease binding affinity for BPC without adversely affecting affinity for HLE.

  DOI：

  10.1021/jm00046a015

文献信息

• Heterocyclic amides
  申请人：Zeneca Limited

  公开号：US05521179A1

  公开（公告）日：1996-05-28

  The present invention relates to certain novel heterocyclic amides which are 1-pyridylacetamide compounds of formula I, set out herein, which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes intermediates useful in the synthesis of these heterocyclic amides, processes for preparing the heterocyclic amides, pharmaceutical compositions containing such heterocyclic amides and methods for their use.

  本发明涉及某些新型杂环酰胺，它们是公式I中所示的1-吡啶乙酰胺化合物，它们是人类白细胞弹性酶（HLE），也称为人类中性粒细胞弹性酶（HNE）的抑制剂，使它们在需要这种抑制作用的情况下有用，例如在药理学、诊断和相关研究中作为研究工具以及在哺乳动物的治疗中HLE被涉及的疾病。本发明还包括用于合成这些杂环酰胺的中间体，制备这些杂环酰胺的方法，含有这些杂环酰胺的药物组合物以及它们的使用方法。
• Inhibitors of interleukin-1 beta converting enzyme
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20020099042A1

  公开（公告）日：2002-07-25

  The present invention relates to novel classes of compounds which are inhibitors of interleukin-1&bgr; converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.

  本发明涉及一种新型化合物类别，其为白细胞介素-1β转化酶抑制剂。本发明的ICE抑制剂具有特定的结构和物理化学特征。本发明还涉及包含这些化合物的制药组合物。本发明的化合物和制药组合物特别适用于抑制ICE活性，因此可以优势地用作对白细胞介素-1介导的疾病，包括炎症性疾病、自身免疫疾病和神经退行性疾病的治疗剂。本发明还涉及使用本发明的化合物和组合物抑制ICE活性的方法和治疗白细胞介素-1介导疾病的方法。
• INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME
  申请人：Bemis Guy W.

  公开号：US20120238749A1

  公开（公告）日：2012-09-20

  The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.

  本发明涉及一类新型化合物，其为白细胞介素-1β转化酶抑制剂。本发明的ICE抑制剂具有特定的结构和物理化学特征。本发明还涉及包含这些化合物的药物组合物。本发明的化合物和药物组合物特别适用于抑制ICE活性，因此可以优势地用作对抗白细胞介素-1介导的疾病，包括炎症性疾病、自身免疫性疾病和神经退行性疾病的药物。本发明还涉及使用本发明的化合物和组合物抑制ICE活性的方法和治疗白细胞介素-1介导的疾病的方法。
• Heterocyclic amides having HLE inhibiting activity
  申请人：ZENECA LIMITED

  公开号：EP0509769A2

  公开（公告）日：1992-10-21

  The present invention relates to certain novel heterocyclic amides which are 1-pyridylacetamide compounds of formula I, set out herein, which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes intermediates useful in the synthesis of these heterocyclic amides, processes for preparing the heterocyclic amides, pharmaceutical compositions containing such heterocyclic amides and methods for their use.

  本发明涉及某些新型杂环酰胺，它们是式I的1-吡啶基乙酰胺化合物，载于本发明中，它们是人白细胞弹性蛋白酶（HLE），也称为人中性粒细胞弹性蛋白酶（HNE）的抑制剂，使得它们在任何需要这种抑制的情况下都有用，例如在药理学、诊断学和相关研究中用作研究工具，以及在治疗哺乳动物中涉及HLE的疾病时。本发明还包括用于合成这些杂环酰胺的中间体、制备杂环酰胺的工艺、含有这些杂环酰胺的药物组合物及其使用方法。
• Inhibitors of interleukin-1beta converting enzyme
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP1394175A1

  公开（公告）日：2004-03-03

  The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.

  本发明涉及一类新型化合物，它们是白细胞介素-1β转换酶的抑制剂。本发明的 ICE 抑制剂具有特定的结构和理化特征。本发明还涉及包含这些化合物的药物组合物。本发明的化合物和药物组合物特别适用于抑制 ICE 的活性，因此可作为抗白细胞介素-1 介导的疾病（包括炎症性疾病、自身免疫性疾病和神经退行性疾病）的药物。本发明还涉及抑制 ICE 活性的方法以及使用本发明化合物和组合物治疗白细胞介素-1 介导的疾病的方法。